Monitor for any update on clinical evidence expansion or partnership announcements that could strengthen a future resubmission. The next key catalyst is the potential June 2027 resubmission; in the interim, watch for any changes in CMS reimbursement policy or competitive developments in breast tumor cryoablation.
Price Chart
Executive Summary
IceCure Medical announced that the AMA's CPT Editorial Panel denied its application to transition from a temporary Category III code to a permanent Category I code for cryoablation of breast tumors, deeming the transition 'premature.' The existing Category III code remains in place, allowing continued CMS reimbursement of approximately $4,000 per facility fee, and the company plans to potentially resubmit in June 2027. This is a clear regulatory setback that delays the path to broader, permanent reimbursement, though near-term commercial operations are unaffected.
Key Facts
- AMA CPT Editorial Panel denied IceCure's application for a permanent Category I CPT code for cryoablation of breast tumors on October 2, 2026.
- The existing temporary Category III code remains in place, allowing CMS reimbursement of approximately $4,000 per facility fee.
- Company plans to potentially resubmit the application in June 2027 after expanding clinical evidence and utilization.
- The decision does not affect current commercial activities under the existing reimbursement framework.
Financial Impact
No immediate financial impact quantified; the denial delays the potential for permanent, higher-reimbursement coding which could have expanded adoption and revenue. The existing $4,000 facility fee remains unchanged.
Risk Factors
- Further delays or denial of permanent CPT I code could limit adoption and revenue growth.
- Competitors may gain market share while IceCure operates under a temporary code.
- Reliance on CMS reimbursement framework; changes in policy could impact facility fee levels.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106619 |
| Document: 0001213900-26-106619-index-headers.html | 0001213900-26-106619 |
| Document: 0001213900-26-106619-index.html | 0001213900-26-106619 |
| Document: 0001213900-26-106619.txt | 0001213900-26-106619 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers